GENE ONLINE|News &
Opinion
Blog

Eli Lilly
In-Depth LawsuitEli LillyNovo Nordisk
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Editors' Picks LiraglutideObesitySemaglutideTirzepatide
Obesity Hope or Hype: Leveraging the Efficacy of Mainstream Weight Loss Pills (Second Part)
2024-03-07
Editors' Picks ObesityEli LillyNovo NordiskTirzepatideSemaglutideLiraglutideNaltrexonebupropion
Obesity Hope or Hype: Leveraging the Efficacy of Mainstream Weight Loss Pills (First Part)
2024-02-15
M&A Eli LillyRadiopharmaceutical
Eli Lilly Expands Oncology Portfolio with $1.4 Billion Acquisition of POINT Biopharma
2023-10-04
Trials & Approvals ObesityDiabetes
Lilly’s Oral GLP-1 Agonist Shows Encouraging Results for Weight Management
2023-06-28
Editors' Picks IL-17VaccineOncology
GeneOnline’s Weekly News Highlights: June 19-23
2023-06-26
Special Insulin
Eli Lilly Caps Insulin At $35 A Month, Widening Access For Americans
2023-03-02
Special JPM
JPM23: More Deals as JP Morgan Healthcare Conference 2023 Enters the Third Day
2023-01-12
Trials & Approvals Jardiance
Eli Lilly and BI Notch Clinical Win for Kidney Disease Drug
2022-11-07
M&A Eli Lilly
Eli Lilly Snatches Up Akouos Treating Ear Conditions for $487 million
2022-10-18
China PD-1 Inhibitor
Innovent, Lilly’s PD-1 Inhibitor Approved to Treat Esophageal Cancer in China
2022-06-21
Trials & Approvals Alopecia Areata
Eli Lilly Nabs FDA Approval For First-Ever Systemic Treatment Targeting Alopecia Areata
2022-06-14
Manufacturing Supply Chain
How Did the Russian Invasion of Ukraine Affect Global Biopharma?
2022-03-16
COVID-19 COVID-19
FDA Gives Emergency Approval for Lilly’s Anti-Omicron Antibody Treatment
2022-02-14
Trials & Approvals Breast Cancer
Eli Lilly’s Early Breast Cancer Drug Gets FDA Nod but Faces Tricky Rollout
2021-10-14
1 2 3 4
LATEST
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
READ MORE
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top